# Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

> **NCT01976741** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 168 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Rogaratinib (BAY1163877) oral solution
- **DRUG:** Rogaratinib (BAY1163877) oral tablet
- **DRUG:** Rogaratinib (BAY1163877) 800 mg BID

## Key facts

- **NCT ID:** NCT01976741
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-30
- **Primary completion:** 2019-03-11
- **Final completion:** 2020-01-09
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01976741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01976741, "Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01976741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*